| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40e710b3b324b6eb307519da1d9bfe7e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cdd5e5ba56b318e0c66467e46236007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6126569e2e16bca1c4ea14038e40f27b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5daa90bda3ea5ab19fb6565770a02a84 |
| publicationDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019043108-A1 |
| titleOfInvention |
TREATMENT AGAINST CANCER |
| abstract |
The present invention relates to the use of mebendazole for the treatment of cancer, the treatment comprising administering to the patient a dose of mebendazole sufficient to achieve a peak steady-state plasma concentration (Cmax) of the mebendazole of 150 to 350 ng / ml (for example 150 to 250, 200 to 300 or 250 to 350 ng / ml). The invention further provides methods of treating cancer, and methods for establishing a therapeutic dose in a cancer patient. |
| priorityDate |
2017-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |